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Cardiovascular autonomic dysfunction, such as orthostatic hypotension consequent to
baroreflex failure and cardiac sympathetic denervation, is frequently observed in the synu-
cleinopathy Parkinson’s disease (PD). In the present study, the baroreceptor reflex was
assessed in mice overexpressing human wildtype alpha-synuclein (Thy1-aSyn), a genetic
mouse model of synucleinopathy. The beat-to-beat change in heart rate (HR), computed
from R–R interval, in relation to blood pressure was measured in anesthetized and con-
scious mice equipped with arterial blood pressure telemetry transducers during transient
bouts of hypertension and hypotension. Compared to wildtype, tachycardia following
nitroprusside-induced hypotension was significantly reduced inThy1-aSyn mice.Thy1-aSyn
mice also showed an abnormal cardiovascular response (i.e., diminished tachycardia) to
muscarinic blockade with atropine. We conclude that Thy1-aSyn mice have impaired basal
and dynamic range of sympathetic and parasympathetic-mediated changes in HR and will
be a useful model for long-term study of cardiovascular autonomic dysfunction associated
with PD.
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INTRODUCTION
Baroreflex failure is documented in patients with Parkinson’s
disease (PD) and is often considered as the root cause for
observed orthostatic hypotension (1, 2). Recently, orthostatic
hypotension, baroreflex failure, and sympathetic denervation have
been reported to occur early in PD, before the onset of overt
motor symptoms, making cardiovascular autonomic dysfunc-
tion a potential PD biomarker for the development of disease-
modifying treatments (3–7). To date few studies have reported
cardiovascular autonomic dysfunction in PD mouse models and
the pathologic mechanisms underlying PD-related cardiovascular
autonomic dysfunction remain to be elucidated (8–11).
In PD, Lewy bodies containing alpha-synuclein have been
observed in peripheral sympathetic areas including stellate gan-
glia and the cardiac plexus, as well as in central brainstem areas
important for regulation of blood pressure and peripheral vascular
resistance and compliance (12–14). Patients with a form of famil-
ial PD associated with alpha-synuclein locus triplication show
impaired baroreflex-cardiovagal gain and reduced cardiac sym-
pathetic innervation suggesting a potentially important role for
alpha-synuclein in the pathogenesis of autonomic dysfunction in
PD (15). Therefore, in this study we sought to characterize barore-
ceptor function in transgenic mice overexpressing alpha-synuclein
under the Thy1 promoter [Thy1-aSyn; (16)]. These mice have
increased alpha-synuclein levels in central and peripheral neurons
and develop proteinase K-resistant alpha-synuclein aggregates
in multiple brain regions, including the substantia nigra, locus
coeruleus, and olfactory bulb (16–18). Thy1-aSyn mice display
both motor and non-motor impairments including gastrointesti-
nal and olfactory dysfunction reminiscent to that observed in PD
(18–22). In addition, by 14 months of age, these mice have a sig-
nificant decrease in striatal dopamine and l-DOPA responsive
behavioral deficits (23). In the present study, we assessed mor-
phometry parameters, baroreceptor reflex, and left ventricular
contractility in Thy1-aSyn and wildtype (WT) mice.
MATERIALS AND METHODS
ANIMALS
Animal care was conducted in accordance with the United States
Public Health Service Guide for the Care and Use of Laboratory
Animals, and procedures were pre-approved by the Institutional
Animal Care and Use Committee at the University of Califor-
nia Los Angeles. Transgenic mice overexpressing human alpha-
synuclein under the Thy1 promoter (Thy1-aSyn) were crossed into
a hybrid C57BL/6-DBA/2 background (16). Animals were main-
tained on the hybrid C57BL/6-DBA/2 background by breeding
mutant females with male mice on the hybrid background (18,
24, 25). Littermates were never inbred. The genotype of all Thy1-
aSyn and WT mice was confirmed with polymerase chain reaction
(PCR) amplification analysis of DNA from tail tips at birth and
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confirmed at the end of the experiment. All mice were individually
housed with free access to water and standard rodent chow.
Male mice from a total of 21 litters were used in this study. Lit-
ter sizes ranged from 2 to 11 mice. Separate cohorts of mice were
used in the hemodynamic-baroreflex protocol (Thy1-aSyn= 9,
WT= 9) and for the heart rate (HR) and contractility dobuta-
mine challenge protocol (Thy1-aSyn= 7; WT= 7) at 9–12 months
of age. An additional separate cohort of mice (Thy1-aSyn= 3–4,
WT= 3–5) was implanted with arterial transducers and tested at
3–5 months of age. A younger cohort in the arterial transducer
experiment was included because the survival rate in older animals
was too low.
MORPHOMETRY
Following hemodynamic assessment surgeries Thy1-aSyn and WT
mice were euthanized and heart, lung, and liver weights were
measured and tibia length determined.
HEMODYNAMIC ASSESSMENT
Hemodynamic assessment was performed as previously described
(26–29). Briefly, in Thy1-aSyn and WT mice anesthetized with
ketamine, xylazine, and buprenorphine, both femoral arteries were
catheterized with flame-stretched PE-50 tubing (30). One catheter
was interfaced to a pressure transducer connected to the PC com-
puter data acquisition system. The other catheter was used for drug
injections. The functionality of the sympathetic and parasympa-
thetic branches of the autonomic nervous system were indepen-
dently evaluated by intravascular injections of the vasoconstricting
α-1 adrenergic receptor agonist phenylephrine (5 and 25µg) and
the vasodilating nitric oxide donor sodium nitroprusside (5 and
15µg). This was followed by autonomic nervous system block-
ers glycopyrrolate (a peripheral acting quaternary amine mus-
carinic receptor antagonist, 20µg) and propranolol (β-adrenergic
receptor antagonist, 50µg) and reinfusions of phenylephrine and
sodium nitroprusside to confirm abolition of the baroreceptor
reflex. All drug injections were administered intrarterially in a vol-
ume of 100µl of 0.9% aqueous saline heparinized at 7 U/ml and
injected over 7 s. HR was determined from the beat-to-beat systolic
pressure peak intervals.
DOBUTAMINE CHALLENGE
We used dobutamine to probe the integrity of the cardiac β-1
adrenergic receptor as reflected in HR and rate of left ventricular
pressure change during systole (inotropic response) and diastole
(lusitropic response). Thy1-aSyn and WT mice were anesthetized
with ketamine, xylazine, and buprenorphine and placed on a
warming pad. HR and temperature were continuously monitored
during surgery. Once anesthetized, the right carotid artery was
catheterized and a 1.4 Fr catheter (Millar Instruments, Hous-
ton, TX, USA) was advanced into the left ventricle to obtain a
dynamic pressure signal that was mathematically differentiated
into in vivo indices of cardiac muscle inotropy (+dP/dT ) and
lusitropy (−dP/dT ) (26). A femoral artery was also catheterized
as above for injection of dobutamine, a β-1 adrenergic receptor
agonist. Dobutamine was injected in serial doses of 3, 6, 15, and
30 ng/g with at least a 5-min recovery period between injections
as an adrenergic post-synaptic receptor challenge test. Measure-
ments were acquired with Hem Software (Notocord Systems V4.2,
Croissy sur Seine, France). HR and left ventricular pressure were
recorded 150 s after injections and averaged over a 10-s period.
Maximum and minimum dP/dT were calculated during this 10-s
period.
TELEMETRIC ASSESSMENT
Arterial pressure and cage activity was measured simultaneously
in awake, freely moving Thy1-aSyn and WT mice using radio
telemetry transducers (TA11PA-C10; Data Sciences International
Inc., St. Paul, MN, USA). Transmitter units were implanted sub-
cutaneously along the mouse’s ventral side under the ketamine,
xylazine, and buprenorphine anesthesia. The transmitter blood
pressure catheter was fed over the shoulder and inserted into
the left carotid artery under sterile surgical conditions (30). Data
recording from the mice began immediately following implan-
tation via an antenna receiver under the cage connected to a
computer system. Pressure waveforms and activity data were col-
lected, analyzed, and displayed with the telemetry software. For all
studies, 20 s of data were collected every 10 min for the duration of
the study. Data waveforms and parameters were analyzed with the
DSI analysis program (ART 4.0) to determine differences in sys-
tolic, diastolic, and mean arterial pressures plus cage activity and
HRs between Thy1-aSyn and WT mice during the entire light-dark
diurnal cycle. Data for the hours surrounding the weekly sched-
uled cage changing were excluded from analysis. The data were
averaged at the same time of day to create “foldagrams” to reveal
any variances (dysfunction) and compare changes between groups
under baseline conditions (30).
We tested tonic vagal release of acetylcholine at the muscarinic
receptor of cardiac pacemaker cells with the muscarinic antagonist
atropine [1 mg/kg, ip; (31)] administered to both Thy1-aSyn and
WT mice. We documented blood pressure and baroreceptor reflex
induced HR changes after phenylephrine [3 mg/kg, ip; (32)] and
sodium nitroprusside [1 mg/kg, sc; (33)]. Each drug was admin-
istered at the same time of day at least 2 days apart to allow for
complete drug clearance from the ip injection. Saline was used
as the vehicle and administered before each drug injection. Blood
pressure and HR were recorded continuously in the home cage,
following saline, and following drug administration.
DATA EXPRESSION AND STATISTICS
The hemodynamic experiment plots (Figures 1A–F) depict the
baseline and acute post-drug pressure and HR data pairs as means
and standard errors, computed as a function of condition, based
on the nine mice in each experimental cell. The slope and R2
statistics were derived with standard bivariate linear regression
analyses, determined from the raw systolic and beats per minute
data pairs, as a function of the genotype× drug conditions, but
collapsed across the three doses of each drug (i.e., n= 27 for each
genotype× drug cell). These and the chronic telemetric data are
also expressed as the ratio of the change in HR in BPM to the
change in systolic blood pressure in mmHg, or ∆HR/∆SBP. For
the dobutamine challenge test and cardiac contractility exper-
iments data are expressed as left ventricular +dP/dT max and
−dP/dT min. A mixed design ANOVA was used to compare geno-
types and dose of drug in the hemodynamic and contractility
experiments. Student’s t -test or Mann–Whitney U were applied
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FIGURE 1 | Systolic pressure and heart rate at baseline (squares) and in
response to phenylephrine (A) and sodium nitroprusside (B) in
anesthetized WT (gray; n=9)Thy1-aSyn (Black; n=9) mice at
9–12 months of age. Mice received 5µg (circles) and 25µg (diamonds) of
intravenous phenylephrine and 5µg (circles) and 15µg (diamonds) of
intravenous sodium nitroprusside. The slope and R2 values were derived from
four separate regression equations, based on all available pairs of systolic
blood pressure (mm/Hg) and heart rate (beats per minute) scores for each
condition and drug, rather than the condition means and standard errors that
are depicted in the plot. The baroreceptor sensitivity index (∆HR/∆SBP)
following serial doses of phenylephrine alone and phenylephrine (25µg/kg)
following autonomic blockade with glycopyrrolate and propanolol (C).
∆HR/∆SBP following serial doses of sodium nitroprusside alone and sodium
nitroprusside (15µg/kg) following autonomic blockade with glycopyrrolate and
propanolol (D). *, **Represents p<0.05, 0.01, respectively compared to WT
at the same dose. Heart rate measurements at baseline (0.0µg/kg) and
following serial doses of phenylephrine [5 and 25µg/kg; (E)]. Heart rate
measurements at baseline (0.0µg/kg) and following serial doses of sodium
nitroprusside [5 and 15µg/kg; (F)]. *Represents p<0.01 compared to WT at
same dose, DD represents p<0.01 compared to baseline (0.0) within same
genotype (Student’s t -test and mixed design ANOVA followed by Fisher’s
LSD).
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to analyze morphometry parameters and arterial telemetry data
between Thy1-aSyn and WT mice. Fisher’s Least Significant Dif-
ference was used for post hoc analyses. All statistics were calculated
with GB-Stat software (Dynamic Microsystems, Inc., Silver Spring,
MD, USA, 2000). The level of significance was set at p< 0.05.
RESULTS
MORPHOMETRY PARAMETERS
Morphometry measures included measurements of body, heart,
liver, and lung weights, and tibia length in Thy1-aSyn and WT
mice (Table 1). Comparisons between WT and Thy1-aSyn mice
using Student’s t -test showed that Thy1-aSyn mice weighed sig-
nificantly less than WT mice, a difference we reported previously
in this mutant line (19). While there were no significant differ-
ences in any of the other measures, heart and liver weights tended
to be smaller in Thy1-aSyn mice but the difference did not reach
significance (p= 0.08 and p= 0.06, respectively).
BASELINE HEART RATE AND SYSTOLIC BLOOD PRESSURE
Baseline systolic blood pressure measurements did not differ
between conscious or anesthetized WT and Thy1-aSyn mice
(p> 0.05). However, baseline HR measures were significantly
different between genotypes under anesthesia during the acute
hemodynamic studies (Table 2); Thy1-aSyn mice had a higher HR
compared to WT mice (p< 0.05). In contrast, conscious WT and
Thy1-aSyn mice equipped with arterial telemetry had comparable
baseline HRs during both the light and dark cycles (Table 2).
HEMODYNAMIC ASSESSMENT
The baroreflex response to the injection of phenylephrine and
sodium nitroprusside in anesthetized Thy1-aSyn and WT mice
are plotted in Figures 1A,B. Though the plots show averaged pres-
sure and heart values for each condition for clarity, the individual
baseline systolic pressures were measured over a wide range of val-
ues from 48 to 159 mmHg in WT mice and from 41 to 157 mmHg
in Thy1-aSyn mice. Linear regression analysis from the raw data
pairs (n= 27 pairs per study) are drawn through the averaged
data points under each condition in Figures 1A,B. These data
are also plotted as the ∆HR/∆SBP score (baroreflex sensitivity
index) in Figures 1C,D. These data clearly show that phenyle-
phrine produced a similar increase in systolic blood pressure and
reflex decrease in HR in WT and Thy1-aSyn mice resulting in
∆HR/∆SBP scores that did not differ between genotypes over
this range of baseline pressures (Figure 1C). As expected with
combined β-adrenergic and muscarinic receptor blockade, the
∆HR/∆SBP response to phenylephrine following β-adrenergic
and muscarinic blockade also did not differ between genotypes
(Figure 1C). In contrast, the response to sodium nitroprus-
side in WT mice showed the characteristic decrease in systolic
blood pressure and increased HR, while in Thy1-aSyn mice sys-
tolic blood pressure decreased but HR remained close to their
initial baseline values regardless of dose (Figures 1B,D). Here,
Thy1-aSyn regression slope was very shallow and ∆HR/∆SBP
scores were significantly lower compared to WT mice (p< 0.05).
The ∆HR/∆SBP response to sodium nitroprusside following
β-adrenergic and muscarinic blockade did not differ between
genotypes (Figure 1D).
Table 1 | Morphometry parameters inThy1-aSyn and wildtype mice at
9–12 months of age.
Wildtype Thy1-aSyn
Body weight (g) 42.12±2.60 31.99±2.36*
Heart weight (mg) 203.43±13.42 172.93±9.75
Lung weight (mg) 203.98±8.35 208.92±27.94
Liver weight (g) 1.45±0.17 1.02±0.12
Tibia length (mm) 18.10±0.21 18.02±0.15
Heart weight/body weight 4.86±0.23 5.50±0.24
Heart weight/tibia length 11.24±0.74 9.59±0.52
*p<0.05 compared to wildtype.
Table 2 | Baseline heart rate and blood pressure (BP) in anesthetized
and awakeThy1-aSyn and wildtype mice.
Genotype Age
(m)
Cycle Heart rate
(beats/min)
Systolic BP
(mmHg)
Wildtype 9–12 Anesthetized Light 489±14 97±4
Thy1-aSyn 9–12 Anesthetized Light 567±25* 106±5
Wildtype 3–5 Awake Light 475±7 108±3
Thy1-aSyn 3–5 Awake Light 498±24 111±3
Wildtype 3–5 Awake Dark 544±13 127±1
Thy1-aSyn 3–5 Awake Dark 589±27 129±3
*p<0.05 compared to wildtype.
Analysis of HR in WT and Thy1-aSyn mice showed phenyle-
phrine caused similar HR decreases in both genotypes follow-
ing administration of phenylephrine [Figure 1E; F(1,16)= 4.33,
p> 0.05 for genotype and F(2,32)= 39.47, p< 0.01 for drug
dose]. However, analysis of HR following sodium nitroprusside
revealed that WT but not Thy1-aSyn showed significant increases
in HR after each dose [Figure 1F; F(1,16)= 1.69, p> 0.05
for genotype and F(2,32)= 25.65, p< 0.01 for drug dose, and
F(2,32)= 7.34, p< 0.05 for genotype× drug dose interaction].
DOBUTAMINE CHALLENGE
Left ventricular inotropy (contraction) and lusitropy (relaxation)
(±dP/dT ) were measured in WT and Thy1-aSyn mice at 9–
12 months of age (Figure 2). Serial infusions of the β-adrenergic
agonist dobutamine resulted in similar left ventricular contrac-
tility (+dP/dT ; Figure 2A) and relaxation (−dP/dT ; Figure 2B)
between WT and Thy1-aSyn mice (p> 0.05). HR responses were
also similar between genotypes (p> 0.05; Figure 2C).
TELEMETRIC ASSESSMENT
Because Thy1-aSyn mice had a higher HR at baseline under anes-
thesia we wanted to determine if the differences we observed were
due to an abnormal response to the anesthesia or to impaired
baroreflex. Therefore, a separate cohort of Thy1-aSyn and WT
mice were implanted with arterial telemetry transducers. Due to
poor post surgery survival at the 9- to 12-month age in Thy1-
aSyn mice the separate cohort of mice for telemetry was younger
in age, 3–5 months. Similar to the hemodynamic experiment
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FIGURE 2 | Left ventricular contractility in WT (n=7) andThy1-aSyn (n=7) at 9–12 months of age. Left ventricular positive dP /dT [contractility; (A)], left
ventricular negative dP /dT [relaxation; (B)], and heart rate following administration of the β-adrenergic agonist dobutamine [(C); mixed design ANOVA].
under anesthesia, conscious mice were challenged pharmacologi-
cally with intraperitoneal phenylephrine and nitroprusside (ip). In
addition the response to muscarinic blockade was measured using
atropine. At 3–5 months of age baseline HR and systolic blood
pressure did not differ between WT and Thy1-aSyn mice. Similar
to the anesthetized experiment WT and Thy1-aSyn mice displayed
comparable responses to phenylephrine and nitroprusside over a
similar range of systolic pressures. There was no difference between
the genotypes in ∆HR/∆SBP or HR scores following phenyle-
phrine injections (p> 0.05; Figures 3A,D). However, in response
to sodium nitroprusside Thy1-aSyn mice once again showed a
blunted HR response while WT showed characteristic tachycardia.
Thy1-aSyn ∆HR/∆SBP scores were significantly decreased com-
pared to WT (p< 0.05; Figure 3B). Analysis of HR alone showed
that HR significantly increased in WT but not in Thy1-aSyn mice
following nitroprusside (p< 0.05; Figure 3E). In response to mus-
carinic blockade ∆HR/∆SBP scores did not significantly differ
between genotypes however, analysis of HR alone showed that HR
significantly increased in WT but not in Thy1-aSyn mice following
atropine (Figures 3C,F). The activity response did not significantly
differ between genotypes in any of the drug conditions (Student’s
t -test, p> 0.05).
DISCUSSION
Baroreflex failure has been reported in both sporadic and alpha-
synuclein associated familial forms of PD (4, 15). While cardio-
vascular autonomic dysfunction is well established in PD, little
is known about the underlying cause of the dysfunction. Until
recently, there has been a lack of basic research on the non-
motor impairments associated with, and often present very early
in humans with PD. However, with the potential early occurrence
of many of the non-motor symptoms, a keen interest in these
symptoms as possible early disease biomarkers has developed. For
example, impaired HR variability observed in REM sleep behav-
ior disorder may be an early indicator of PD (7). In the present
study we show that overexpression of human alpha-synuclein in
mice leads to impaired baroreflex control of HR prior to changes
in striatal dopamine content and reminiscent of the baroreflex
dysfunction observed in PD (1, 2). These findings are important
because they provide a foundation for future studies aimed at
identifying brain structures and pathological mechanisms associ-
ated with cardiovascular autonomic dysfunction in PD. In addi-
tion, these results underscore the usefulness of Thy1-aSyn mice in
the study of early non-motor symptoms associated with PD.
Overall, with the exception of body weight, morphometry mea-
sures did not statistically differ between genotypes. We have pre-
viously reported decreased body weight in Thy1-aSyn compared
to WT mice at 12 months of age without differences in overall
food intake (19). We did however note a trend for heart and liver
weights to be decreased in Thy1-aSyn mice.
The most profound functional differences were observed in
response to administration of the vasodilator sodium nitroprus-
side. Here, anesthetized WT mice displayed the characteristic
tachycardic response to the sudden drop in blood pressure pro-
duced by sodium nitroprusside, over a wide range of initial
baseline values. But the Thy1-aSyn mice showed no significant
change in HR during an equivalent transient decrease in systolic
blood pressure suggesting impairments in autonomic modula-
tion of cardiac function in Thy1-aSyn mice at an early age, before
reductions in striatal dopamine content are observed (23). Dur-
ing these experiments it was noted that Thy1-aSyn mice appeared
more sensitive than WT to the anesthetic combination of keta-
mine, xylazine, and buprenorphine. This is consistent with a recent
study in the same Thy1-aSyn mouse line where the authors report
increased sensitivity to the common rodent anesthetic xylazine
(22). Due to this increased sensitivity it is possible that the HR dif-
ferences observed in the Thy1-aSyn mice could be due in part to
the anesthesia and not impaired baroreflex function. Therefore, we
performed an additional set of experiments where WT and Thy1-
aSyn mice were equipped with arterial telemetric transducers to
allow HR and SBP measurements in conscious/awake mice. In this
experiment we found that baseline HR and SBP were not different
between genotypes suggesting the difference seen in anesthetized
mice may have been a consequence of abnormal response to the
anesthesia, or only develop at a later age. However, HR and SBP
responses to phenylephrine and sodium nitroprusside were similar
to what we observed in the previous experiments under anesthesia.
In Thy1-aSyn mice sodium nitroprusside administration resulted
in a significant decrease in SBP and a blunted HR response. Typi-
cally, during a drop in blood pressure efferent sympathetic outflow
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FIGURE 3 | Baroreceptor sensitivity, ∆HR/∆SBP, in awakeThy1-aSyn
(n=3–5) and WT (n=3–4) mice at 3–5 months following systemic
administration of phenylephrine (A), sodium nitroprusside (B), and
atropine (C). Heart rate responses following systemic phenylephrine (D),
sodium nitroprusside (E), and atropine (F). *Represents p<0.05 compared to
WT, ∆ represents p<0.05 compared to baseline (0.0 mg/kg) within same
genotype (Mann–Whitney U and mixed design ANOVA followed by Fisher’s
LSD).
is increased (34, 35). Thus, in the present study the blunted HR
response to sodium nitroprusside suggests the sympathetic com-
ponent of the baroreflex is impaired in Thy1-aSyn mice over a wide
range of ages. In PD patients with or without orthostatic hypoten-
sion, a similar blunted HR increase has been reported in response
to the feet down tilt maneuver and in the Valsalva maneuver (5, 36,
37). It has been proposed that the combination of baroreflex fail-
ure and widespread noradrenergic denervation contributes to the
development of orthostatic and post-prandial hypotension and
supine hypertension commonly seen in PD (38).
Adrenergic supersensitivity in response to sympathetic den-
ervation has been reported in patients with PD (39). Therefore,
similar to Nakamura et al. (39) we tested left ventricular contrac-
tility of the heart in response to administration of the β-adrenergic
agonist dobutamine in WT and Thy1-aSyn mice. There were no
significant differences in inotropy or lusitropy between WT and
Thy1-aSyn mice indicating no evidence of receptor supersensitiv-
ity. This is consistent with a recent finding showing no differences
in contractility in patients in the early stages of PD (40).
Acetylcholine released from parasympathetic nerves reduces
HR by binding primarily to M2 subtype muscarinic receptors on
sinoatrial nodal cells in the heart. Blockade of M2 muscarinic
receptors results in an increase in HR (31). In the present study
WT but not Thy1-aSyn mice showed a significant increase in
HR in response to the systemic muscarinic antagonist atropine.
In addition, although not statistically significant (p= 0.08), WT
mice showed a mean increase in HR in response to glycopyrro-
late while Thy1-aSyn mice showed on average a decrease in HR in
response to the peripheral muscarinic antagonist. The abnormal
response to atropine in Thy1-aSyn mice is similar to a recent study
measuring HR variability parameters in mice that express A53T
mutant human alpha-synuclein under the Thy1 promoter. Here,
the authors show increased baseline HR and reduced change in HR
in response to systemic atropine in A53T compared to WT mice
suggesting parasympathetic dysfunction in the mutant mice (11).
However in contrast, mice with A53T or A30P mutations in alpha-
synuclein generated using PAC transgenesis showed no alterations
in HR variability parameters at 12 months of age, perhaps due
to the low level of expression of the transgenic protein (10). The
abnormal cardiovascular response to atropine taken together with
the impaired HR response to sodium nitroprusside and previ-
ous work showing gastrointestinal dysfunction in Thy1-aSyn mice
suggest impairment of both sympathetic and parasympathetic sys-
tems in Thy1-aSyn mice (19, 20). Thus, the Thy1-aSyn mice show a
potentially broader range of autonomic anomalies than previously
reported in other mouse models of synucleinopathy (10, 11).
The pathological mechanisms underlying cardiovascular auto-
nomic dysfunction in PD remain unclear. In PD sympathetic
denervation is observed in patients with and without orthosta-
tic hypotension and has been reported to develop before and
after the diagnosis of PD (4, 38, 41). In addition to sympa-
thetic denervation alpha-synuclein containing Lewy bodies can be
observed in cardiac and brain regions important for sympathetic
regulation of blood pressure and HR in humans suggesting that
alpha-synuclein pathology may contribute to cardiovascular auto-
nomic anomalies commonly observed in PD (12–14). In the brain
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of Thy1-aSyn mice human alpha-synuclein mRNA expression is
high throughout the brainstem and proteinase K-resistant alpha-
synuclein inclusions develop in the locus coeruleus and substantia
nigra (16, 17). In a recent study in the same line of Thy1-aSyn mice
human alpha-synuclein protein was observed in the ventricular
and atrial walls of the heart localized within noradrenergic fibers
(22). Thus, it is unclear at this point whether the functional impair-
ments are associated with either peripheral or central pathology or
a combination of both. Functional deficits in central noradrenergic
and dopaminergic systems have been observed in this mouse line
(23, 24, 42, Maidment and Chesselet, unpublished observations)
and dysregulation of central noradrenergic and dopaminergic sys-
tems has been shown to alter baroreceptor function in rodents
suggesting central catecholamine system dysfunction could be a
contributing factor (8, 27). Sodium nitroprusside, in addition to
its peripheral vasodilator actions, is also known to activate central
noradrenergic neurons in the locus coeruleus (43). Interestingly,
the most profound impairment in Thy1-aSyn mice was a lack
of nitroprusside-induced tachycardia, which was shown in both
anesthetized and awake conditions. However, further research is
needed to determine the exact contribution of peripheral and
central noradrenergic and dopaminergic dysfunction in the auto-
nomic regulation of blood pressure and HR in Thy1-aSyn mice.
CONCLUSION
The present study shows that Thy1-aSyn mice, a model of
synucleinopathy, have impaired baroreflex control of HR anal-
ogous to what is observed in patients with the synucleinopa-
thy PD (5, 36, 37). Furthermore, the cardiovascular auto-
nomic dysfunction detected in the Thy1-aSyn mice occurs
prior to dopaminergic alterations in the striatum. Similarly
in PD cardiovascular autonomic dysfunction is also reported
to occur early, before the onset of overt motor symptoms.
While the mechanisms contributing to cardiovascular anom-
alies in PD remain to be established the Thy1-aSyn mice pro-
vide a novel genetic model in which to study the contribu-
tion of alpha-synuclein pathology to autonomic dysfunction
in PD.
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